BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics

Source:
British Society for Rheumatology - BSR
Publisher:
British Society for Rheumatology (BSR)
Publication date:
25 July 2013

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy affecting up to 40% of patients with skin or nail psoriasis. The previous BSR guidelines for the use of anti-TNF therapies in PsA were published in 2005, at which time,only one compound was licensed for use in active PsA in the UK (etanercept), and only one other anti-TNF therapy had evidence for the efficacy in PsA (infliximab).

These guidelines offer systematic and evidence-based recommendations for the prescription of anti-TNF therapies in adult PsA patients to support UK clinicians in their use. The guidelines cover adult patients with PsA affecting all domains of psoriatic disease. They provide a stepwise management plan giving clear advice on treatment from initial diagnosis including inclusion/exclusion criteria for treatment, monitoring requirements and how to quantify response to biologics. They provide evidence-based advice for the use of anti-TNF therapies in difficult situations including pregnancy and significant comorbidities.